BetterLife Pharma Inc. (CSE: BETR) has retained LifeSci Advisors to manage its investor relations and corporate communications activities, the company announced on October 27, 2026. The engagement is designed to broaden awareness of BETR-001, a non-hallucinogenic neuroplastogen in development for chronic cluster headache and chronic migraine, as the company targets an Investigational New Drug (IND) application submission in the first quarter of 2027. The appointment follows a USD$100 million financing and additions to BetterLife's Scientific Advisory Board, signalling a period of active development momentum that investors may be watching closely.

Key Points

  • BetterLife Pharma Inc. (CSE: BETR | OTCQB: BETRF | FSE: NPAU) is a Vancouver-based biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine.
  • LifeSci Advisors has been retained for investor relations and corporate communications, effective October 27, 2026.
  • Monthly fees total USD$26,750 (USD$24,250 for IR services and USD$2,500 for key media programs); LifeSci will receive no equity-based compensation; the initial term is twelve months.
  • Investors may be watching BetterLife's targeted Q1 2027 IND submission and planned clinical development initiation during that year.

LifeSci Advisors Mandate and Fee Structure for BETR Investor Outreach

Under the terms of the engagement, LifeSci Advisors will receive monthly cash fees of USD$24,250 for investor relations services and USD$2,500 for key media programmes, including media outreach and social media development, for a combined monthly cost of USD$26,750. The firm will receive no equity-based compensation. The agreement runs for an initial term of twelve months and will automatically renew for successive twelve-month periods unless sixty days' prior written notice is provided by either party. LifeSci will deliver services through digital marketing, email newsletters, social media, conference coordination, and direct investor outreach.

BETR-001 Development Status and IND Timeline

BETR-001 is a non-hallucinogenic derivative of 2-bromo-lysergic acid diethylamide (2-Br-LSD) being developed as a potential preventive treatment for chronic cluster headache and chronic migraine. BetterLife holds a granted U.S. composition-of-matter patent covering BETR-001. The company is targeting submission of an IND application in the first quarter of 2027, with plans to initiate clinical development during that year. BETR-001 remains an investigational product and has not been approved by any regulatory authority. No medical or health benefit claims have been confirmed by approved research.

USD$100 Million Financing and Scientific Advisory Board Strengthen BetterLife's Position

The investor relations appointment follows two significant milestones disclosed by BetterLife. The company recently closed a USD$100 million financing led by Deep Track Capital, with co-investments from Coastlands Capital, Marshall Wace, RA Capital Management, and Perceptive Advisors, among other healthcare-focused institutional investors. Separately, internationally recognised headache experts Professors Peter Goadsby and Richard Lipton were appointed as Co-Chairs of BetterLife's Scientific Advisory Board. Together, these developments reflect a broadening institutional profile that the LifeSci engagement is intended to support as clinical milestones approach.